Nobody has counted BPC-157 side effects in a controlled human trial, so any list quoting frequencies is describing something that was never measured. The whole human record is three small uncontrolled reports. We'd rather hand you that absence than a fabricated table.
BPC-157 has no controlled human safety data. Not thin data. None. The human record is three small reports with no controls and zero randomized trials. Animal toxicity work looks clean, but 35 of the 36 studies in the 2025 review are animal models, and roughly 80% come from one group.
This is an uncomfortable page to write, because the honest answer disappoints the search. You came for a list. What exists instead is an absence, and we think the shape of that absence is more useful to you than a made-up table would be.
What does the human safety record on BPC-157 contain?
The human safety record on BPC-157 is three papers, all from one research group, none of them controlled. Two are pilot studies and one is a retrospective case series. Here they are in full.
- A knee-pain case series (Lee & Padgett, 2021) — retrospective, uncontrolled, intra-articular injection. No adverse-event framework.
- An interstitial cystitis pilot (Lee et al., 2024) — small, uncontrolled.
- An intravenous safety pilot (Lee & Burgess, 2025) — the only study in the set designed around safety, and it is a pilot.
Three reports, one research group, no control arms, no placebo, no systematic adverse-event collection. That's the entire human safety literature. The knee series in context covers what it can and can't support.
What does the animal safety work on BPC-157 show?
The BPC-157 animal toxicity picture is genuinely unremarkable, and that's worth saying plainly rather than burying. Four decades of rodent work spans wound healing, gut, tendon, nerve and vascular models.
Across all of it, the literature reports no characteristic toxicity, no LD50 of concern and no consistent organ signal. For a compound tested this widely in animals, the absence of a toxicity signature is a real observation.
What animal safety cannot tell you. Rodent studies detect acute and subacute toxicity. They're poorly suited to what actually ends human drug programs: rare idiosyncratic reactions, immunogenicity, drug interactions, and effects that take years to surface.
BPC-157's mechanism runs partly through VEGFR2 and angiogenesis. On that pathway, "promotes new blood vessel growth" is the therapeutic claim and the theoretical oncological concern at once. No study has looked.
What have regulators concluded about BPC-157?
| Body | Position | What it means |
|---|---|---|
| FDA (2023) | Category 2 for compounding | Significant safety risk identified; effectively closes the 503A pharmacy route |
| WADA | Prohibited, class S0 | S0 is "no approval by any regulatory authority for human use" — a status category, not a toxicity finding |
The FDA's Category 2 designation is the substantive one. It reflects a judgment that BPC-157's safety data is too thin to support compounding. That's a statement about the evidence, not a report of harm observed.
BPC-157
The reference compound behind the preclinical literature reviewed here. Research use only, supplied with a batch-matched certificate of analysis.
What BPC-157 risk is actually documented?
The one documented BPC-157 risk isn't pharmacological. It's contamination. Research-grade material carries no sterility assurance and no routine endotoxin testing.
Endotoxin is heat-stable, survives filtration of the powder, and isn't what a purity assay measures. So a vial can be 99% pure BPC-157 and still cause an injection-site or systemic reaction from whatever came along with it.
That's the failure mode with an evidence base behind it, and it's a sourcing problem rather than a compound problem. Our note on what a certificate does and doesn't cover is where you'd start.
Frequently asked questions
Does BPC-157 have side effects?
Nobody knows, because no controlled human trial has ever measured BPC-157 side effects. The animal literature reports no characteristic toxicity, but animal studies can't detect the effects that typically end human drug programs.
Is BPC-157 safe?
Unanswerable on current evidence, and we won't pretend otherwize. Safety in the regulatory sense needs controlled trials with systematic adverse-event collection. BPC-157 has three small uncontrolled human reports.
Why did the FDA flag BPC-157?
In 2023 the FDA placed BPC-157 in Category 2 for compounding. That's a judgment that the available safety data can't support pharmacy preparation. It's a statement about the evidence rather than a report of observed harm.
Does BPC-157 cause cancer?
No study has looked, so you won't find an answer either way. The theoretical concern comes from the mechanism: BPC-157 acts partly through VEGFR2 and angiogenesis, and promoting new blood vessel growth is both the therapeutic rationale and the theoretical risk.
What is the most likely adverse reaction in practice?
Something introduced with the BPC-157 rather than by it. Research-grade peptides carry no sterility assurance or routine endotoxin testing, and an HPLC purity assay doesn't detect endotoxin.
BPC-157
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- There is no controlled human safety data on BPC-157. Not limited data, none at all.
- The entire human record is three small reports, none of which had a control group.
- Animal toxicity work looks very clean, but 35 of the 36 studies in the 2025 review are animal models.
- Roughly 80% of that work comes from one research group, which narrows how independent the picture is.
- Any side-effect list quoting percentages is describing something nobody has actually measured in humans.
What we’re watching
We're watching for a BPC-157 trial that collects adverse events systematically, with a control arm. Until one publishes, this page can only describe an absence.
We're also watching the FDA's periodic 503A category review. A move out of Category 2 would mean the agency had seen safety data nobody has published yet.
References
- Vasireddi, N., Hahamyan, H., Salata, M. J., et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal, 21(4). https://doi.org/10.1177/15563316251355551
- McGuire, F. P., Martinez, R., Lenz, A., Skinner, L., & Cushman, D. M. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 18(12), 611–619. https://doi.org/10.1007/s12178-025-09990-7
- Lee, E., & Padgett, B. (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27(4), 8–13. PMID 34324435
- Lee, E., Walker, C., & Ayadi, B. (2024). Effect of BPC-157 on symptoms in patients with interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine, 30(10), 12–17. PMID 39325560
- Lee, E., & Burgess, K. (2025). Safety of intravenous infusion of BPC-157 in humans: A pilot study. Alternative Therapies in Health and Medicine, 31(5), 20–24. PMID 40131143
- U.S. Food and Drug Administration. (2024). Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
- U.S. Food and Drug Administration. (2024). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding